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Abstract
Background: In Finland, the annual number of MRSA notifications to the National Infectious
Disease Register (NIDR) has constantly increased since 1995, and molecular typing has revealed
numerous outbreak isolates of MRSA. We analyzed the data on MRSA notifications of the NIDR,
and MRSA isolates were identified mainly by pulsed-field gel electrophoresis (PFGE) at the National
Reference Laboratory (NRL) in Finland during 1997–2004. One isolate representative of each
major PFGE type was further characterized by multilocus sequence (MLST)-, staphylococcal
cassette chromosome mec (SCCmec)-, and Panton-Valentine leukocidin (PVL)-typing.
Results: The annual number of MRSA notifications to the NIDR rose over ten-fold, from 120 in
1997 to 1458 in 2004, and the proportion of MRSA among S. aureus blood isolates tripled, from
<1% during 1997–2003 to 2.8% in 2004. During the same period of time, 253 different strains
among 4091 MRSA isolates were identified by PFGE: 215 were sporadic and 38 outbreak/epidemic
strains, including 24 new strains. Two epidemic strains resembling internationally recognized MRSA
clones accounted for most of the increase: FIN-16 (ST125:IA) from <1% in 1997 to 25% in 2004,
and FIN-21 (ST228:I) from 6% in 2002 to 28% in 2004. Half of the ten most common strains carried
SCCmec IV or V.
Conclusion: The predominant MRSA strains seem to change over time, which encourages us to
continue implementing active control measures with each new MRSA case.
Background
Methicillin-resistant  Staphylococcus aureus (MRSA) has
become a persistent problem worldwide. MRSA has been
established as a major hospital pathogen but it has also
been found increasingly in long-term facilities, and in
communities from persons having no connection to the
health-care setting [1]. It is generally accepted that hospi-
tal-acquired MRSA isolates spread to the long-term facili-
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ties as well as to the community. However, the
community-based isolates may migrate into the health-
care settings, and thus create a two-way flow of MRSA [2].
Of the genotyping methods, pulsed-field gel electrophore-
sis (PFGE) has been suggested to be the golden standard
for local outbreak investigations [3], and multi locus
sequence typing (MLST) and the mobile genetic element,
staphylococcal cassette chromosome mec (SCCmec)-typ-
ing [4,5] for understanding the evolution of different
MRSA clones [6]. SCCmec types I-III, and IVA have been
associated with hospital acquisition, and types IV and V
are mostly found in strains circulating in the community
[7]. Several major different pandemic MRSA clones have
been identified mainly by PFGE, i.e. Iberian, Brazilian,
Hungarian, New York/Japan, Pediatric, and UK EMRSA-
15 and -16 clones [8]. MLST has, however, revealed that
several MRSA clones, considered to be distinct by using
PFGE and other molecular typing techniques, were indis-
tinguishable [9]. Using MLST and eBURST, the five most
common pandemic MRSA lineages can be grouped as
clonal complexes: CC5, CC8, CC22, CC30, and CC45.
Several nationwide studies on molecular epidemiology of
MRSA have also been performed [10-14]. However, the
extensiveness of the MRSA isolate collections used in
those studies varied, and most of the studies were based
on selected isolates as opposed to all MRSA isolates being
identified on the national level.
The purpose of our study was to examine the molecular
epidemiology of MRSA in Finland during 1997–2004 in
comparison to European and pandemic MRSA clones by
using the nationwide collection including all MRSA iso-
lates, thus giving an insight into the trends of MRSA evo-
lution at the nationwide level over a certain period of
time. We also performed a survey which focused on the
background information of the MRSA-positive persons in
2001–2003.
Results and Discussion
Our study is based on comprehensive collection of MRSA
isolates obtained nationwide, and during 1997–2004,
4026 MRSA notifications were received by the NIDR
(120–1458 per year). The annual incidence of MRSA rose
over ten-fold, from 2.3 notifications per 100,000 popula-
tion in 1997 to 27.9 in 2004 (Figure 1). Among the 4026
MRSA notifications, 71 specimens were obtained from
blood and 4 from CSF; 30 of the blood isolates and 3 of
the CSF isolates were from 2004. The proportion of MRSA
among blood isolates of S. aureus rose from under 1% to
2.8% in 2004, although it is still low compared with many
other countries in Europe or worldwide [15,16]. During
1997–2004, the numbers of MRSA notifications were
strikingly high in three HDs and in six others there was an
increasing trend. In 1997, the incidence of MRSA was
slightly over 10 notifications per 100,000 population only
in the Helsinki metropolitan area, whereas the incidence
rate rose to over 20 notifications per 100,000 population
in eight HDs by 2004.
During the same period of time a total of 4091 MRSA iso-
lates were studied in the reference laboratory. PFGE iden-
tified 253 different strains of which 38 were outbreak/
epidemic strains, and 215 sporadic (Figure 2). Twenty-
four new outbreak/epidemic strains appeared during
1997–2004. The proportion of sporadic strains varied
between 3–13% during the study period. There is a slight
difference in the numbers of MRSA notifications and
MRSA isolates (65), this is partly due to the differences in
the case definitions (a time interval of 12 months versus
36 months); also if the same person had two different
types of isolates, both of them were included (a total of 27
persons carried two different strains). There may also exist
some MRSA notifications of which the MRSA isolate was
not sent to the reference laboratory and vice versa.
At the beginning of the study period (1997–2001), the
distribution of different MRSA strains was more diverse,
but since 2002, five strains (FIN-16 (ST125:IA), FIN-4
(ST375:IV), FIN-21 (ST228:I), FIN-7 (ST8:IV), and FIN-10
(ST45:IV and V) have been most predominant (Table 1).
The number of internationally recognized epidemic
strains, FIN-16 (ST125:IA), a single-locus variant of ST5
(New York/Japanese clone) – named previously Bel EC-3
– and FIN-21 (ST228:I), has strongly increased since
2003. In 2004 more than half of the isolates (53%) were
composed of FIN-16 and FIN-21. The most common
MRSA isolates found from blood and from CSF in 2004
were FIN-16 (12/34), of FIN-21 (9/34), and of FIN-4 (4/
34); no significant associations were found between the
type of specimen (blood and CSF vs. other) and these
strains in 2004 nor during the whole study period.
The proportion of FIN-16 (ST125:IA) strains increased
from <1% in 1997 to 25% in 2004. The majority of all
FIN-16 strains (554/742) were found in one HD in central
Finland, and it has dominated in that area since 2001, but
it also extended to 14 other HDs. Pérez-Roth and others
have reported a similar increase of ST125:IV strains in
Spanish hospitals [17]. Our survey (2001–2003) showed
that FIN-16 strains were more likely to be found from
clinical specimens than from those obtained on screening
and other basis (199 [25%] of 805 vs. 160 [18%] of 902;
p < 0.05) (Table 2), and it was the most common strain
found from invasive specimens in 2004 indicating that
FIN-16 might be of epidemic potential and virulent. Since
FIN-16 has dominated in one HD for four years it can be
considered an endemic strain in that area, especially in
long-term facilities. Thus, we can equally assume that its
capacity to cause clinical infections may occur becauseBMC Infectious Diseases 2007, 7:94 http://www.biomedcentral.com/1471-2334/7/94
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FIN-16 strain has reached a sufficiently high level in the
population, especially among the oldest and most seri-
ously ill patients who are being transferred between long-
term facilities and acute care hospitals.
The FIN-21 (ST228:I) strain was found in Finland for the
first time in September 2002 [18]. Its proportion
increased from 6% in 2002 to 28% in 2004, and it
occurred mostly in the Helsinki metropolitan area (98%;
572/581) where it caused many epidemic clusters during
2002–2004. The strain has a similar PFGE pattern to the
Italian clone [12], expresses MLST allelic profile ST 228, a
double-locus variant of ST5, and SCCmec type I. MRSA
strains with the same ST228 have also been reported as
the "Southern Germany" epidemic clone [19]. The strain
tended to be found more often from screening and other
specimens than from those taken on clinical basis (58
[7%] of 805 vs. 87 [10%] of 902; p = 0.086) (Table 2), as
opposed to FIN-16. This may be due to differences in the
MRSA screening activity between the HDs, or the later
appearance of the strain in Finland. We have previously
shown that during 2001, the screening activity varied
widely between the HDs (0–2768 per 100,000 popula-
tion), but it was not related to the rate of MRSA [20].
UK EMRSA-16, currently named as FIN-6 (ST36:II),
decreased from 13% in 1997 to <1% in 2003, and FIN-3
(ST5:II) from 18% to 3%, respectively. UK EMRSA-15,
now FIN-12 (ST22:IV) varied between 1–6%. This is in
contrast to the situation in the UK where the same strains
(UK EMRSA-15 and -16) are predominant [21]. In Spain
a rapid nosocomial dissemination of an identical strain
(UK EMRSA-16) has been reported [17], and also in Swe-
den it caused a large outbreak in hospital setting [22]. In
our material, FIN-12 was the most commonly found
strain, 14/19 (74%), among staff members screened
because of hospital contact abroad (Table 2).
More than half of the MRSA strains carried SCCmec IV or
V (Figure 2), which are often seen in community-acquired
MRSA (CA-MRSA) [7]. One of the three strains which was
previously associated with community-acquisition [23],
FIN-4 (ST375:IV, a single locus variant of ST59), was the
second most common strain (Table 1). FIN-4 was more
likely to be found among isolates obtained from patients
and staff members on clinical basis than in screening (167
[21%] of 805 vs. 81 [9%] of 902; p < 0.05) (Table 2) in
addition to FIN-16. It has been found in every HD during
the study period (range of annual numbers in HDs 7–17).
Annual incidence of MRSA notifications per 100,000 population, and the proportion of MRSA among S. aureus blood isolates,  Finland, 1997–2004 Figure 1
Annual incidence of MRSA notifications per 100,000 population, and the proportion of MRSA among S. aureus blood isolates, 
Finland, 1997–2004.
0
0.5
1
1.5
2
2.5
3
1997 1998 1999 2000 2001 2002 2003 2004
P
r
o
p
o
r
t
i
o
n
 
o
f
 
M
R
S
A
 
a
m
o
n
g
 
b
l
o
o
d
 
i
s
o
l
a
t
e
s
 
(
%
)
0
5
10
15
20
25
30
I
n
c
i
d
e
n
c
e
 
p
e
r
 
1
0
0
 
0
0
0
 
p
o
p
u
l
a
t
i
o
n
MRSA proportion (%) IncidenceBMC Infectious Diseases 2007, 7:94 http://www.biomedcentral.com/1471-2334/7/94
Page 4 of 9
(page number not for citation purposes)
Dendrogram of the epidemic MRSA strains based on the Dice coefficient of pattern similarity, obtained after SmaI macror- estriction analysis of DNA of MRSA isolates Figure 2
Dendrogram of the epidemic MRSA strains based on the Dice coefficient of pattern similarity, obtained after SmaI macror-
estriction analysis of DNA of MRSA isolates. Strains which were found first time in Finland during 1997–2004 are indicated by 
"a". Slv means single locus variant, and dlv means double locus variant.
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MRSA isolates of ST59 are considered as one of the most
divergent MRSA sequence types [9]. ST59 has been
reported in a few MSSA isolates from the United States
[24], and in a few MRSA isolates in Asian countries
[25,26]. ST375, a single locus variant of ST59, has recently
been shown to spread as CA-MRSA in Denmark [27].
Unfortunately, no health-care records were available in
the present study, and we cannot assess whether acquisi-
tion of FIN-4 strain is still associated with community.
The two other prevalent SCCmec  IV expressing strains,
FIN-7 (ST8:IV) and FIN-10 (ST45:IV) were more likely to
be found in screening specimens of patients and staff
members than in their clinical specimens (70 [9%] of 805
vs. 194 [22%] of 902; p < 0.05, and 89 [11%] of 805 vs.
149 [17%] of 902; p < 0.05) (Table 2). FIN-15 (ST8:IV)
caused an epidemic in a health-care facility in Eastern Fin-
land in 2000, and since then, the strain has been found
occasionally during 2000–2004.
In addition to the presence of SCCmec type IV or V, the
presence of lukS-PV and lukF-PV-genes along with epide-
miological data are generally used in the definition of CA-
MRSA. Of the representative strains, FIN-11 (ST80:IV) and
FIN-25 (ST8:IV) were PVL positive (Figure 2). In addition,
some strains of FIN-5 (ST30:IV) and FIN-19 (ST1:IV) pos-
sessed lukS-PV – lukF-PV genes encoding PVL. The major-
ity of all MRSA isolates which were previously associated
with community-acquisition possessed type IV SCCmec,
but only a minority (12%) of them were PVL positive
[28]. Most of these PVL-positive isolates were of ST80 as
reported elsewhere [27,29]. However, although many iso-
lates found in the community harbor these markers, trans-
mission of "CA-MRSA" strains between health-care
settings and community may occur [30].
Of FIN-2 strains, FIN-2e (ST241:IIIB) subtype caused an
outbreak in Southern Finland in 1999, and only a few
strains have been found since then. FIN-2e is a single
locus variant of ST239, which is the main ST of FIN-2
strain, and thus it is possible that FIN-2e may have
evolved from the FIN-2 by a point mutation. FIN-2 strain
includes isolates possessing three different SCCmec types
(SCCmec III, IIIA, and IIIB; Figure 2), indicating that this
strain may have received the mecA gene several times or
SCCmec may have been modified. This may be true also
with both of FIN-1 and FIN-10 strains which possess two
different SCCmec types (SCCmec IA and IVA, and SCCmec
IV and V, respectively).
The annual proportion of sporadic strains decreased dur-
ing the study period, although the total number increased
slightly, indicating that new strains appear constantly.
Among the patient findings, more than half of the spo-
radic strains were derived from clinical specimens, 23%
from screening specimens based on exposure to MRSA,
20% from screening specimens based on hospital contact
abroad, and 2% were other indications (Table 2). The spo-
radic strains were found most often from specimens taken
Table 1: Ten most common Finnish epidemic MRSA strains analyzed by PFGE (one per person) 1997–2004.
aMRSA 
strain
Sequence 
type (ST) 
and 
SCCmec 
type
1997 1998 1999 2000 2001 2002 2003 2004 Overall No. of 
hospital 
districts 
in which 
the strain 
found 
(total n = 
20)
F I N - 1 6 S T 1 2 5 : I A 12632 1 1 0 3 2 3 1 3 7 5 7 4 2 1 5
F I N - 4 S T 3 7 5 : I V 3 33 94 66 59 37 29 41 8 3 6 2 5 2 0
F I N - 2 1 S T 2 2 8 : I 000003 2 1 1 8 4 3 1 5 8 1 3
FIN-7 ST8:IV 4 12 12 10 41 145 83 188 495 16
FIN-10 ST45:IV, 
V
15 16 16 48 28 69 146 110 448 17
F I N - 3 S T 5 : I I 2 5 2 1 8491 6 4 6 4 4 1 7 3 1 4
F I N - 1 5 S T 8 : I V 0002 5 92 7 3 2 3 3 1 2 6 7
F I N - 1 2 S T 2 2 : I V 2931 3 1 4 2 2 2 2 2 7 1 1 2 1 6
bFIN-2 ST241:III
B
064 4 843257 2 7
F I N - 6 S T 3 6 : I I 1 8 1 4 761 1 7116 5 1 1
Other 
strains
27 59 53 35 61 58 59 85 437 20
Sporadic 12 19 17 32 33 25 31 46 215 19
Total 137 197 212 249 324 579 865 1528 4091
aMRSA strains include related patterns with a 1–6 band differences.
bThis represents only FIN-2e subtype.BMC Infectious Diseases 2007, 7:94 http://www.biomedcentral.com/1471-2334/7/94
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because of a hospital contact abroad (30%; 19/64). Blanc
and co-workers have reported that at least one-third of the
sporadic isolates found in Switzerland were due to an
ongoing introduction of new isolates from abroad [10].
They have also shown that most of the sporadic Swiss iso-
lates were related to other European epidemic MRSA
clones [31]. We cannot be confident of the origin of our
sporadic strains because our routine molecular typing
scheme is primarily based on the highly discriminatory
PFGE, which allows detection of genomic microevolution
only. A thorough MLST and eBURST analysis as well as
spa typing might have revealed whether our sporadic
strains have descended from a few ancestors.
In Finnish acute care hospitals the control of MRSA is
based on active culture screening and contact isolation.
The increase in the incidence of MRSA remained one of
the lowest in Southwestern Finland in comparison with
the other regions. In the beginning of the 90's, the first
three major MRSA outbreaks in Southwestern Finland and
the Helsinki metropolitan area were successfully control-
led [32-34]. Later, molecular typing revealed numerous
smaller outbreaks [13]. In 2001 the number of MRSA
cases rose in elderly persons outside the Helsinki metro-
politan area, suggesting an emerging problem in long-
term care [20]. Consequently, the national guidelines for
control of MRSA were updated to cover also long-term
facilities.
Regardless of a strict control policy, the most recent MRSA
manifestations in Central and Southern Finland were
related to the spread of two internationally recognized
MRSA strains, FIN-16 and FIN-21, and these two strains
also caused the striking increase in blood and CSF find-
ings. The outbreaks were, however, different in their epi-
demiology: FIN-16 prevailed in long-term facilities and
FIN-21 in acute care hospitals. During the survey period
(2001–2003), the proportion of screening specimens
increased among the patients and staff members, and
almost half of the MRSA isolations were recovered from
patients' screening specimens (Table 2), reflecting the
active screening policy. The increase in the screening activ-
ity may partly be related to the increase in the MRSA cases
we detected, especially in cases with FIN-21 [18], but it is
unlikely that it had an influence on the worrying trend in
blood and CSF findings. In addition, the implementation
of control measures may not have been in accordance
with the presumptions, which may be due to the lack of
resources in some hospital districts or in some settings.
Although we had only limited data on clinical infections
Table 2: Background information on patients and staff members who tested positive for the ten most common epidemic MRSA 
strains, 2001–2003. The response rate of the survey was 97% (1707/1768).
MRSA 
strain
Number of patients (n = 1598) Number of staff members (n = 109) Total no. 
of isolates
Sequence 
type (ST) 
and 
SCCmec 
type
Clinical 
specimen
aScreening 
specimen; 
exposure 
to MRSA
bScreening 
specimen; 
hospital 
contact 
abroad
Other 
reason for 
taking the 
sample
Clinical 
specimens
cScreening 
specimen; 
epidemic 
situation
dScreening 
specimen; 
hospital 
contact 
abroad
Other 
reason for 
taking the 
sample
FIN-16 ST125:IA 197 131 5 18 2 3 1 2 359
FIN-7 ST8:IV 70 159 1 6 - 28 - - 264
FIN-4 ST375:IV 163 56 5 12 4 8 - - 248
F I N - 1 0 S T 4 5 : I V ,  V 8 7 1 2 9 2621 2 --2 3 8
FIN-21 ST228:I 58 82 1 3 - 1 - - 145
FIN-3 ST5:II 22 30 8 7 - 4 - - 71
FIN-15 ST8:IV 34 19 - 5 - 9 - 1 68
FIN-12 ST22:IV 19 12 8 4 - 1 14 - 58
F I N - 6 S T 3 6 : I I 515--11-1 3
eF I N - 2 S T 2 4 1 : I I I B 7-2-----9
Other 
strains
7 9 4 9 8235221 5 0
S p o r a d i c 5 2 2 2 1 9 2111-9 8
T o t a l 7 9 3 6 9 0 6 46 51 27 31 95 f1721
aScreening specimens of MRSA increased from 36% (96/265) in 2001 to 45% (364/816) in 2003.
bHospitalized or undergone a surgical procedure outside the Nordic countries within 6 months
cScreening specimens of MRSA increased from 46% (12/26) in 2001 to 82% (36/44) in 2002, but decreased to 64% (25/39) in 2003.
dWorked outside the Nordic countries within 6 months
eThis represents only FIN-2e subtype.
fThe total number of strains (1721) exceeds the number of MRSA-positive persons (1707) by 14, because in some cases more than one reason for 
sampling was chosen in the questionnaire.BMC Infectious Diseases 2007, 7:94 http://www.biomedcentral.com/1471-2334/7/94
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caused by MRSA, and could not differentiate screening
specimens from those taken on clinical basis over the
whole study period, we believe that the spread of MRSA
has increased, as indicated by each new MRSA case. To
guarantee appropriate resources in infection control in all
HDs the Ministry of Social Affairs and Health allocated
additional funds to MRSA for the years 2005–6. Thus far,
this special investment may have paid off since the rising
incidence of new MRSA cases seems to have slowed down
(data not shown). However, a permanent trend in the
near future remains to be seen.
Conclusion
The predominant MRSA strains change over time, but two
internationally spread epidemic strains of MRSA were
related to the increase of MRSA incidents detected most
recently, and those strains were also the cause of the strik-
ing increase of invasive MRSA findings, thus showing the
real worsening of the situation in Finland. In addition, the
rise in MRSA strains with SCCmec types IV or V, possible
CA-MRSA, was similar to other European countries
[27,29]. The future will show if active control measures
will still function in controlling MRSA in this new setting.
Methods
Surveillance of MRSA
In Finland (population 5.2 million), the national health
care system is organized into 20 geographically and
administratively defined hospital districts (HD), with
populations ranging from 67.800 to 1.7 million. Fifteen
HDs have only secondary and primary care hospitals, and
five provide also tertiary care services. Finnish clinical
microbiology laboratories notify all MRSA isolations to
the National Infectious Disease Register (NIDR) at the
National Public Health Institute (KTL). KTL records the
date, source of specimen, and the date of birth, sex, and
treatment place of the patient. Using this information and
a time interval of 36 months, multiple notifications from
the same person are combined as one in the database. In
case of blood or cerebrospinal fluid (CSF) specimens, the
time interval is three months.
Typing scheme of MRSA
The microbiology laboratories send all MRSA isolates to
the National Reference Laboratory (NRL) at KTL for con-
firmation and typing. The analyses include bacterial iden-
tification, antimicrobial susceptibility testing, mecA and
nuc detection by PCR as previously described [20], and
genotype analysis by PFGE [19]. PFGE patterns are ana-
lyzed by BioNumerics (version 1.0 or 2.0, Applied Maths,
Belgium) by using the Dice coefficient to analyze the sim-
ilarity of the banding patterns, and the unweighted pair
group method using arithmetic averages (UPGMA) for
cluster analysis. After initial classification by computer
assisted analysis, the patterns are further interpreted
according to established guidelines [35]. PFGE patterns
with 7 or more band differences are considered different
types. PFGE patterns with 1–6 band differences are con-
sidered as subtypes.
The S. aureus PFGE database at KTL is used as the basis for
naming the isolates (after naming of the isolates, they are
called strains). The database covers all Finnish epidemic
MRSA strains, including three strains that have previously
been associated with community-acquisition [13,23], and
the Harmony collection [19]. If the PFGE profile repre-
sents a previously recognized Harmony collection profile,
the isolate has been named accordingly. Since 2005, all
MRSA strain names have become numeric. Subtypes are
additionally labelled with letters. Sporadic strains have
been defined as those found only from one person during
the study period 1997–2004. Outbreak/epidemic strains
of MRSA were isolated from more than one person. For
the analysis, only one strain per person was included
except with persons showing two or more different
strains. Representative isolates, one per PFGE type, were
further characterized by MLST [5], and by a multiplex PCR
for the determination of the presence of Panton-Valentine
leukocidin (PVL) genes (lukS-PV – lukF-PV) [36], SCCmec
type I-IV [4], a PCR for the detection of ccr-gene and mec-
gene complex [37], and by PCR for the detection of ccrC
of type V SCCmec [7] as described earlier.
Control of MRSA
The control measures include screening of patients
exposed to MRSA. The minimum of screening sites
include nostrils, wounds, and exit sites of devices. Patients
are considered exposed if they have shared a room with a
MRSA patient or have been hospitalized on a ward where
MRSA transmission has occurred from one patient room
to another; the latter group covers patients who have been
recently hospitalized abroad. Patients with MRSA infec-
tion and colonization are nursed in contact isolation (use
of apron or gown and gloves) in a single room or in
cohorts with designated staff during their hospital stay,
the same applies to patient exposed to MRSA until the
appearance of MRSA has been ruled out. Staff is screened
only if MRSA transmission continues despite ordinary
control measures or if the transmission chain remains
unclear.
Survey
During 2001–2003, a more detailed surveillance was per-
formed by collecting demographic and epidemiological
data from persons positive for MRSA by sending question-
naires to infection control nurses at the relevant health
care institutions. The information collected included 1)
whether the MRSA positive person was a patient or a staff
member, 2) whether the specimen was taken on clinical
or screening basis, 3) whether the patient was screenedBMC Infectious Diseases 2007, 7:94 http://www.biomedcentral.com/1471-2334/7/94
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because of a hospital contact abroad (hospitalized or
undergone a surgical procedure outside the Nordic coun-
tries within 6 months) or because of an exposure to
MRSA, and the staff member because of a hospital contact
abroad (worked outside the Nordic countries within 6
months) or because of an epidemic situation, and 4)
whether the specimen was taken for some other reason.
Statistical analysis
For categorical variables, proportions were compared by
the chi-square test with Yates correction or Fisher's exact
test, as appropriate. The p-values of < 0.05 were consid-
ered significant.
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